RT期刊文章SR电子T1超优的中等强度的影响(MS) ICS-containing三联疗法在急性加重哮喘患者与持久的气流限制:三体帆船的因果分析研究摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP PA3719做10.1183/13993003.国会- 2019。188bet官网地址PA3719 VO 54 IS supp63 A1 Virchow, J. Christian A1 Paggiaro, Pierluigi A1 Canonica, Walter Giorgio A1 Kuna, Piotr A1 Kots, Maxim A1 Corre, Sandrine A1 Vele, Andrea A1 Georges, George A1 Petruzzelli, Stefano YR 2019 UL //www.qdcxjkg.com/content/54/suppl_63/PA3719.abstract AB在吸入糖皮质激素和长效β2受体激动剂(ICS/LABA)的哮喘患者中，持续气流限制(PAL)可能预测添加长效毒蕈碱拮抗剂(LAMA)的临床阳性反应。目的和目的:我们评估了二丙酸倍氯米松/富马酸福莫特罗/溴化甘氨溴铵(BDP/FF/GB)对pal患者哮喘加重的影响。TRIMARAN是一项III期跨国、随机、平行组试验，比较了52周的(BDP/FF/GB) 400/24/50 μ g/d至BDP/FF 400/24 μ g/d经加压计量吸入器(pMDI)治疗的未控制哮喘成人患者中、中剂量ICS/LABA和过去一年有哮喘加重史的治疗。PAL定义为400 μg沙丁胺醇pMDI后FEV1≤预测正常的80%，FEV1/FVC≤0.7。结果:1155名被试随机分组，658名(57.0%)符合PAL标准的BDP/FF/GB标准(n=331)和BDP/FF标准(n=327)。与BDP/FF治疗组相比，BDP/FF治疗组中、重度哮喘发作年发生率分别降低了15.2%和37.7%，(RR [95% CI] = 0.848 [0.694, 1.036]， p=0.106;0.623 (0.430;0.902]， p=0.012)，而在整个研究人群中分别为15.4% (p=0.033)和26.3% (p=0.040)。结论:在使用中剂量ICS/LABA的哮喘患者中，PAL不影响精外MS BDP/FF/GB减轻中重度发作的疗效，且与年重度发作率的更大降低相关。本文脚注如下:欧洲呼吸杂志2019;54:补编63,PA3719。This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).